Table 6.

 Mean difference in cognitive decline in global score between aspirin compared with placebo groups: effect modification by major risk factors for cognitive decline*

Characteristics	Mean difference (95% CI)	P for interaction
Age (years) at first cognitive assessment:
<75	0.00 (−0.03 to 0.03)	0.16
≥75	0.06 (−0.02 to 0.13)
Cognitive performance at first assessment:
Below median	0.02 (−0.02 to 0.07)	0.49
Above median	0.00 (−0.03 to 0.04)
Self reported perceived change in memory†:
None or improved	0.00 (−0.03 to 0.03)	0.21
Worse	0.05 (−0.02 to 0.12)
Highest attained education:
LPVN, associates degree, or registered nurse	0.02 (−0.02 to 0.05)	0.56
Bachelors degree, masters degree, or doctorate	0.00 (−0.05 to 0.05)
Cigarette smoking:
Never	−0.01 (−0.05 to 0.03)	0.03
Former	0.01 (−0.03 to 0.06)
Current	0.13 (0.03 to 0.22)
Alcohol consumption:
Less than weekly	0.01 (−0.02 to 0.05)	0.94
Weekly	0.01 (−0.05 to 0.06)
Daily	0.00 (−0.08 to 0.08)
Body mass index:
<30	0.01 (−0.02 to 0.04)	0.96
≥30	0.01 (−0.06 to 0.08)
Physical exercise:
Less than once weekly	0.03 (−0.01 to 0.07)	0.14
Once or more weekly	−0.02 (−0.06 to 0.03)
Hormone replacement therapy use:
Never	0.00 (−0.04 to 0.05)	0.69
Ever (former plus current)	0.01 (−0.02 to 0.05)
Diabetes:
Yes	0.13 (−0.03 to 0.29)	0.15
No	0.01 (−0.02 to 0.04)
Hypertension:
Yes	−0.02 (−0.06 to 0.03)	0.17
No	0.03 (−0.01 to 0.06)
Raised cholesterol level:
Yes	0.05 (0.01 to 0.09)	0.02
No	−0.02 (−0.06 to 0.02)
Depression‡:
Yes	0.09 (−0.04 to 0.21)	0.20
No	0.00 (−0.03 to 0.03)
Cardiovascular disease during follow-up§:
Yes	0.08 (−0.04 to 0.20)	0.24
No	0.00 (−0.03 to 0.03)

LPVN=licensed practical or vocational nurse.

*Characteristics at randomisation, unless stated otherwise.

†Assessed at run-in phase.

‡Assessed four years after randomisation.

§Includes non-fatal myocardial infarction, non-fatal stroke, revascularisation surgery, or cardiovascular death.